SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the introduction of CHO.SET® 2.0. The expanded library of novel and patentable synthetic promoters is designed to improve protein production in CHO (Chinese Hamster Ovary) cells.

Image Credit: SynGenSys

The CHO.SET Library® was first introduced in 2024, and has since been expanded and optimised, reflecting SynGenSys' continued commitment to addressing critical biomanufacturing bottlenecks. Current market vectors rely heavily on natural promoters such as CMV and SV40E, which have restricted transcriptional activity and are therefore insufficient for generating the high productivities required for modern commercial biotechnology applications. Developed de novo using the Company's proprietary transcriptional analysis and sequence engineering platform, CHO.SET® synthetic promoters combine advanced computational design with empirical validation to deliver a highly diverse promoter library applicable across a wide range of CHO expression systems and biomanufacturing requirements.

New supporting data demonstrate that CHO.SET® promoters outperform standard industry promoters, delivering enhanced transcriptional activity and improved protein production metrics. Selected vectors have been shown to achieve over 4x higher antibody productivity, with titers exceeding 2 g/L in a simple fed-batch flask model. The CHO.SET® synthetic promoter pools also contain a higher proportion of high-expressing cells, increasing the likelihood of isolating top-performing clones. CHO.SET® supports more efficient and streamlined cell line development workflows, achieving high titers without the need for MSX, reducing process complexity and enabling faster recovery timelines and route to materials for toxicity studies. 

CHO cells are the pharmaceutical industry's gold-standard cell factories, and CHO cell-specific synthetic promoters provide an elegant solution to overcoming key productivity limitations in the industry. We are excited to release this latest update and to continue providing solutions that address evolving biomanufacturing needs."

Dr Andrew Racher, Co-CEO, SynGenSys 

 The CHO.SET Promoter Library® will be showcased at BioProcess International this September as part of Biotech Week Boston.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SynGenSys Ltd.. (2026, August 13). SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing. News-Medical. Retrieved on August 13, 2026 from https://www.news-medical.net/news/20260813/SynGenSys-introduces-expanded-CHOSET-synthetic-promoter-library-for-enhanced-biomanufacturing.aspx.

  • MLA

    SynGenSys Ltd.. "SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing". News-Medical. 13 August 2026. <https://www.news-medical.net/news/20260813/SynGenSys-introduces-expanded-CHOSET-synthetic-promoter-library-for-enhanced-biomanufacturing.aspx>.

  • Chicago

    SynGenSys Ltd.. "SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing". News-Medical. https://www.news-medical.net/news/20260813/SynGenSys-introduces-expanded-CHOSET-synthetic-promoter-library-for-enhanced-biomanufacturing.aspx. (accessed August 13, 2026).

  • Harvard

    SynGenSys Ltd.. 2026. SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing. News-Medical, viewed 13 August 2026, https://www.news-medical.net/news/20260813/SynGenSys-introduces-expanded-CHOSET-synthetic-promoter-library-for-enhanced-biomanufacturing.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.